Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,007 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles.
Barata P, Gulati S, Elliott A, Hammers HJ, Burgess EF, Gartrell BA, Darabi S, Bilen MA, Basu A, Geynisman DM, Dawson NA, Zibelman MR, Zhang T, Wei S, Ryan CJ, Heath EI, Poorman KA, Nabhan C, McKay RR. Barata P, et al. Among authors: basu a. J Clin Invest. 2024 Apr 23:e178915. doi: 10.1172/JCI178915. Online ahead of print. J Clin Invest. 2024. PMID: 38652565 Free article.
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC. Freeman MN, et al. Among authors: basu a. Oncologist. 2022 Mar 11;27(3):220-227. doi: 10.1093/oncolo/oyab057. Oncologist. 2022. PMID: 35274720 Free PMC article.
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Barata P, et al. Among authors: basu a. Front Oncol. 2020 Oct 22;10:581189. doi: 10.3389/fonc.2020.581189. eCollection 2020. Front Oncol. 2020. PMID: 33194712 Free PMC article.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Koshkin VS, et al. Among authors: basu a. Cancer. 2022 Mar 15;128(6):1194-1205. doi: 10.1002/cncr.34057. Epub 2021 Dec 9. Cancer. 2022. PMID: 34882781 Free article.
3,007 results